Blenrep belantamab Injection

Product Description

1. Technical Specifications

---

2. Product Description

Blenrep (Belantamab Mafodotin) is a monoclonal antibodydrug conjugate (ADC) that targets B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells in multiple myeloma.

• The antibody portion binds selectively to BCMA.

• The attached cytotoxic agent (monomethyl auristatin F MMAF) disrupts microtubules, leading to apoptosis (cell death).

It is prescribed for relapsed or refractory multiple myeloma (RRMM) in adults who have received at least 4 prior therapies (including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent).

---

3. Product Highlights

---

4. Therapeutic Uses

• Multiple Myeloma (Relapsed or Refractory) after 4 prior lines of therapy.

---

5. Side Effects

Common:

• Vision changes, blurred vision, dry eyes, keratopathy (eye toxicity)

• Fatigue, fever

• Nausea, decreased appetite

• Anemia, thrombocytopenia

• Infusion-related reactions

Serious / Severe:

• Severe ocular toxicity (corneal damage)

• Severe thrombocytopenia (risk of bleeding)

• Serious infusion reactions

• Secondary malignancies (rare but possible)

---

6. Precautions

• Ocular Monitoring: Eye exams are required before treatment and prior to each dose. Patients may need preservative-free lubricating eye drops.

• Blood Monitoring: CBC for anemia, neutropenia, and thrombocytopenia.

• Dose Adjustments: Required in case of severe eye or hematologic toxicity.

• Pregnancy & Breastfeeding: Contraindicated; may cause fetal harm. Effective contraception advised.

• Driving / Machinery: Avoid activities requiring clear vision if experiencing blurred vision or eye discomfort.

• Drug Interactions: Limited data, but caution with other immunosuppressants and drugs affecting bone marrow.

Targeted Therapy for Multiple Myeloma

Blenrep Injection offers a unique therapeutic approach for adults diagnosed with multiple myeloma, especially for those whose condition has proved refractory to previous treatments. Its targeted mechanism can provide new hope for improved disease management and quality of life under the supervision of healthcare specialists.


Strict Storage and Handling Protocols

Maintaining the integrity of Blenrep is crucial. The product must be stored in a cool, dry environment, away from direct sunlight. Proper storage ensures its stability and effectiveness during administration. Distributors and suppliers are advised to adhere to these protocols throughout the supply chain.